Clinical Trial Update: IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating IMM0306 in combination with lenalidomide versus placebo in combination with lenalidomide for relapsed/refractory follicular lymphoma. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• IMM0306
• Lenalidomide (lenalidomide)

Snippet

Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Conditions: Relapsed/Refractory Follicular Lymphoma | Phase 3 | Status: NOT_YET_RECRUITING